Dianthus Therapeutics, Inc. (DNTH)
| Market Cap | 4.56B |
| Revenue (ttm) | 2.04M |
| Net Income (ttm) | -162.34M |
| Shares Out | 54.45M |
| EPS (ttm) | -4.20 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 499,658 |
| Open | 87.12 |
| Previous Close | 87.16 |
| Day's Range | 83.41 - 89.18 |
| 52-Week Range | 16.64 - 96.50 |
| Beta | 0.21 |
| Analysts | Strong Buy |
| Price Target | 121.00 (+44.62%) |
| Earnings Date | May 6, 2026 |
About DNTH
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell functio... [Read more]
Financial Performance
In 2025, Dianthus Therapeutics's revenue was $2.04 million, a decrease of -67.35% compared to the previous year's $6.24 million. Losses were -$162.34 million, 91.1% more than in 2024.
Financial StatementsAnalyst Forecast
According to 13 analysts, the average rating for DNTH stock is "Strong Buy." The 12-month stock price target is $121.0, which is an increase of 44.62% from the latest price.
News
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK and WALTHAM, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to ...
Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
NEW YORK and WALTHAM, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH) (“Dianthus” or the “Company”), a clinical-stage biotechnology company dedicated to developing...
Dianthus Therapeutics, Inc. Announces Pricing of Upsized $625 Million Underwritten Public Offering
NEW YORK and WALTHAM, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH) (“Dianthus” or the “Company”), a clinical-stage biotechnology company dedicated to developing...
Dianthus Therapeutics, Inc. Announces Proposed $400 Million Underwritten Public Offering
NEW YORK and WALTHAM, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH) (“Dianthus” or the “Company”), a clinical-stage biotechnology company dedicated to developing...
Dianthus Therapeutics Stock Rallies—Rare Disease Study Success Fuels Optimism
CIDP is a rare, acquired autoimmune disorder where the immune system damages the myelin sheath of peripheral nerves, causing progressive or relapsing muscle weakness, numbness, and sensory loss lastin...
Dianthus Therapeutics Transcript: Study result
An interim analysis of the CAPTIVATE phase 3 trial in CIDP led to an early go decision, with efficacy surpassing expectations and a strong safety profile. Study design changes will expedite completion, and the program is well positioned for future milestones and competitive advantage.
Dianthus Therapeutics Highlights Recent Business Achievements, Including GO Decision for Phase 3 CAPTIVATE CIDP Trial, and Reports Q4 and FY 2025 Financial Results
Early GO decision reached in CAPTIVATE ahead of Q2'26 guidance based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants completing open-label Part A
Dianthus Therapeutics Announces Early GO Decision Following Interim Responder Analysis in Phase 3 CAPTIVATE Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Early GO decision reached ahead of Q2'26 guidance based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants completing open-label Part A Key objectives achieved:...
Dianthus Therapeutics to Host Conference Call and Webcast to Discuss the Interim Responder Analysis Results of the Phase 3 Captivate Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
NEW YORK and WALTHAM, Mass., March 08, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to ...
Dianthus Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
Strong phase II data in MG and rapid recruitment in CIDP position the program for key milestones in 2024, with interim CIDP results expected in Q2 and MMN phase II data in the second half. Patient-friendly trial design and differentiation from competitors support a favorable outlook.
Dianthus Therapeutics to Participate in The TD Cowen 46th Annual Health Care Conference
NEW YORK and WALTHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to t...
Dianthus Therapeutics Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026
Major clinical milestones are expected in 2026 for CIDP, MMN, and DNTH212, with strong efficacy and safety positioning versus competitors. Commercial potential is significant, supported by a robust cash position extending into 2028.
Dianthus Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
NEW YORK and WALTHAM, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to t...
Dianthus Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference
Two clinical-stage autoimmune therapeutics are advancing, with claseprubart showing robust efficacy and superior potency in MG, CIDP, and MMN, and DNTH212 targeting diseases driven by both innate and adaptive immunity. Key data readouts and regulatory milestones are expected throughout the year.
Dianthus Therapeutics To Participate in the 44th Annual J.P. Morgan Healthcare Conference
NEW YORK and WALTHAM, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to t...
Leads Biolabs And Dianthus Therapeutics Announce Initiation of Phase 1 Trial Of LBL-047 (DNTH212) In Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE)
LBL-047 (DNTH212) is a bifunctional fusion protein targeting plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B ce...
Dianthus Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference
Recent phase II data has de-risked the pipeline, accelerating CIDP trial timelines and supporting a competitive efficacy profile. Key catalysts are expected in 2026, with ongoing optimization of dosing and trial design across neuromuscular programs.
Dianthus Therapeutics To Participate in the 8th Annual Evercore Healthcare Conference
NEW YORK and WALTHAM, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to t...
Dianthus Therapeutics Transcript: Jefferies London Healthcare Conference 2025
Two autoimmune therapies are advancing, with Claseprubart showing strong phase II MG results and a phase III program set to test both biweekly and monthly dosing. DNTH212, targeting both innate and adaptive immunity, enters phase I soon. Key data readouts for MG, CIDP, and MMN are expected in 2026.
Dianthus Therapeutics Transcript: Stifel 2025 Healthcare Conference
Claseprubart, a C1s inhibitor, is advancing to phase III for MG and CIDP, aiming for best-in-class efficacy, improved safety, and less frequent dosing. A new bifunctional fusion protein expands the pipeline, with multiple clinical readouts expected through 2027.
Dianthus Therapeutics Transcript: TD Cowen Immunology and Inflammation Summit
Claseprubart's phase 3 trials in gMG and CIDP are advancing, with new dosing strategies and streamlined trial designs driving faster enrollment and differentiation from competitors. Auto injector implementation and regulatory alignment are key priorities.
Dianthus Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference
Significant phase II efficacy for claseprubart in MG supports advancement to phase III with optimized dosing and screening. Accelerated CIDP trial timelines and robust operational execution position the pipeline for potential paradigm shifts in neuromuscular disease treatment.
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results
Claseprubart achieved statistically significant and clinically meaningful improvements in Myasthenia Gravis Activities of Daily Living (MG-ADL), Quantitative Myasthenia Gravis (QMG), and other efficac...
Dianthus Therapeutics to Participate in Four Investor Conferences During November
NEW YORK and WALTHAM, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to t...
Dianthus Therapeutics Highlights New Claseprubart Data Presented During 2025 AANEM Annual Meeting
Positive data from Phase 2 MaGic trial presented for claseprubart in generalized Myasthenia Gravis, including new open-label extension data further supporting potential for 300mg/2mL Q4W dosing